Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study
Dose escalation with biologics for UC in the USA is common. This practice has substantially increased the average medication cost of biologics to payers/patients compared to their approved doses. .
Authors
- Richard Moses (ORCID: https://orcid.org/0000-0002-1423-089X)
- Tania Gulati
- Deborah A. Fisher (ORCID: https://orcid.org/0000-0002-8886-3382)
- Ashmita Bandyopadhyay
- Navneet Upadhyay (ORCID: https://orcid.org/0000-0003-3776-9596)
- Miguel D. Regueiro (ORCID: https://orcid.org/0000-0002-7681-8111)
- Thomas Creveling
- Payal Jha
Institutions
- Cleveland Clinic (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Digestive Diseases
- Published
- 2025-08-16
- DOI
- https://doi.org/10.1159/000547994
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82